Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.
about
Polychromatic flow cytometry in evaluating rheumatic disease patientsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisRituximab for Rheumatoid Arthritis.Prospective data collection of off-label use of rituximab in Australian public hospitals.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationLow- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosusB lymphocyte-typing for prediction of clinical response to rituximab.A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Rituximab for the treatment of rheumatoid arthritis: an update.B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Rituximab biosimilars.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Emerging immunotherapies for rheumatoid arthritis.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.Response to Dr Bredemeier's letter.An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression.Reply
P2860
Q26827075-03057FD9-9EA8-4959-B3AD-356FE2279BD7Q26852081-EEDE58F9-F0C8-49FE-A894-577C75318BADQ28080246-538E7824-1E58-4B85-B2E6-7E59E2C239BFQ30640279-9F84E83F-0643-4274-A5E0-B88DFB0B1D82Q31046441-1F226151-1EC3-4274-8FF3-FE7853823C62Q34975404-4FFB410D-59A2-4C42-9139-C74A678508CCQ36469965-3DA5C932-7BFA-43EC-B632-D7EE7426F0B6Q36532571-2494496A-7A2E-4132-82B5-52457F5DED59Q36633292-2F699C52-9D83-4D21-AE33-5727B5A57EC5Q37203531-742A5853-5610-40ED-BD4A-1B3944B4A057Q37388213-77B6E70F-33C0-4E6C-BF16-E93AD56248A9Q37444678-1450447F-FB30-465A-9414-99C5203F9E13Q38097129-7C3CD003-98F9-4A90-975B-F390ECD22F2AQ38097170-47B7AFCE-B930-446C-9034-2C077EE37F4BQ38100232-4D8F66CB-9DEB-4845-AABE-585C571E45FAQ38154934-E3D72EEE-D73A-492A-947C-C6BF920FC5D9Q38188862-571639E5-38B6-4CD2-BE6B-84D485CAB9BCQ38408710-5C712041-223D-42EB-A3BA-D6EA4F0FF5CCQ38753455-11AE838D-5FC2-41B5-8032-260A75785A63Q38838249-868038ED-7E07-4597-9168-E94548438D41Q38857820-558B0987-6A84-42CE-8FE2-81A81A649E05Q39708039-818D821A-4E27-489B-8D31-F64FB0A2CD9CQ41571651-12480887-A928-42C1-AFC2-9D3BC645A16EQ50772450-3CBB309A-632E-43DE-A34D-529A8AA076B4Q52839527-C869809C-814B-4735-82A9-A2238F784CF7Q52840072-65DEB604-5E11-426A-99AD-55C4F663A4CEQ52840446-1C10C2D9-7D1E-4D54-B43C-DDCC3709F1F0Q53178921-43709693-6E21-48E5-8E97-2F155E177A43Q57987446-C05C6526-56A0-494D-97A9-5AAEFF34D9FE
P2860
Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en-gb
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@nl
type
label
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en-gb
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@nl
prefLabel
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en-gb
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@nl
P2093
P2860
P50
P356
P1476
Reduced-dose rituximab in rheu ...... on degree of B cell depletion.
@en
P2093
Julie Madden
Karen Henshaw
Shouvik Dass
P2860
P304
P356
10.1002/ART.30152
P577
2011-03-01T00:00:00Z
P5875
P6179
1009036359